Wall Street brokerages predict that NuCana PLC (NASDAQ:NCNA) will report earnings of ($0.23) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for NuCana’s earnings, with estimates ranging from ($0.28) to ($0.18). NuCana posted earnings of ($0.28) per share in the same quarter last year, which suggests a positive year over year growth rate of 17.9%. The firm is expected to report its next quarterly earnings report on Wednesday, May 22nd.
Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for NuCana.
Separately, Zacks Investment Research upgraded shares of NuCana from a “hold” rating to a “strong-buy” rating and set a $22.00 price target on the stock in a research report on Tuesday, December 4th.
Shares of NuCana stock traded down $0.15 during trading on Tuesday, hitting $16.35. 1,343 shares of the company’s stock were exchanged, compared to its average volume of 88,057. NuCana has a 52-week low of $10.37 and a 52-week high of $32.00. The stock has a market cap of $512.16 million, a PE ratio of -29.85 and a beta of 4.20.
NuCana Company Profile
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.
Recommended Story: Cost of Equity For A Business, Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.